What happens when drugs with accelerated approval turn out not to work? CP3 Director Walid Gellad told Axios, "If there's no proof the drug has value, then why should we pay the same as if the drug had proof of value?”
What happens when drugs with accelerated approval turn out not to work? CP3 Director Walid Gellad told Axios, "If there's no proof the drug has value, then why should we pay the same as if the drug had proof of value?”